JP2011521896A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011521896A5 JP2011521896A5 JP2011505028A JP2011505028A JP2011521896A5 JP 2011521896 A5 JP2011521896 A5 JP 2011521896A5 JP 2011505028 A JP2011505028 A JP 2011505028A JP 2011505028 A JP2011505028 A JP 2011505028A JP 2011521896 A5 JP2011521896 A5 JP 2011521896A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical formulation
- antagonist
- lfa
- aryl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000005557 antagonist Substances 0.000 claims description 51
- 102100022339 Integrin alpha-L Human genes 0.000 claims description 48
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 48
- 125000001072 heteroaryl group Chemical group 0.000 claims description 39
- 125000003118 aryl group Chemical group 0.000 claims description 38
- 229910052739 hydrogen Inorganic materials 0.000 claims description 27
- 239000001257 hydrogen Substances 0.000 claims description 27
- 125000001931 aliphatic group Chemical group 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 24
- 150000002431 hydrogen Chemical class 0.000 claims description 24
- 125000002723 alicyclic group Chemical group 0.000 claims description 22
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 22
- -1 heteroaliphatic Chemical group 0.000 claims description 22
- 125000000623 heterocyclic group Chemical group 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical group 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 150000002148 esters Chemical class 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 claims description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 8
- 239000002674 ointment Substances 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000006210 lotion Substances 0.000 claims description 7
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 claims description 6
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 125000002070 alkenylidene group Chemical group 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- BWOVZCWSJFYBRM-UHFFFAOYSA-N carbononitridic isocyanate Chemical group O=C=NC#N BWOVZCWSJFYBRM-UHFFFAOYSA-N 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 229910052740 iodine Inorganic materials 0.000 claims description 6
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- 239000003889 eye drop Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- 229920001400 block copolymer Polymers 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 229940051250 hexylene glycol Drugs 0.000 claims description 4
- 230000001050 lubricating effect Effects 0.000 claims description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 4
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 4
- 229960002216 methylparaben Drugs 0.000 claims description 4
- 239000003961 penetration enhancing agent Substances 0.000 claims description 4
- 229920005862 polyol Polymers 0.000 claims description 4
- 150000003077 polyols Chemical class 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims description 3
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 3
- JTNFLOSMZURXJM-UHFFFAOYSA-N NS(S)(=O)=O Chemical compound NS(S)(=O)=O JTNFLOSMZURXJM-UHFFFAOYSA-N 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 230000002424 anti-apoptotic effect Effects 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 125000004104 aryloxy group Chemical group 0.000 claims description 3
- VCJIGSOOIYBSFA-UHFFFAOYSA-N azido formate Chemical compound [N-]=[N+]=NOC=O VCJIGSOOIYBSFA-UHFFFAOYSA-N 0.000 claims description 3
- 239000000227 bioadhesive Substances 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 230000002860 competitive effect Effects 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 3
- 239000011859 microparticle Substances 0.000 claims description 3
- 125000002950 monocyclic group Chemical group 0.000 claims description 3
- 239000002105 nanoparticle Substances 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- 239000011505 plaster Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 3
- 229960003415 propylparaben Drugs 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 238000011200 topical administration Methods 0.000 claims description 3
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims description 3
- 239000002525 vasculotropin inhibitor Substances 0.000 claims description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical group CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- 108010036949 Cyclosporine Proteins 0.000 claims description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- NMLMACJWHPHKGR-NCOIDOBVSA-N P(1),P(4)-bis(uridin-5'-yl) tetraphosphate Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N2C(NC(=O)C=C2)=O)O)O)C=CC(=O)NC1=O NMLMACJWHPHKGR-NCOIDOBVSA-N 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- ALLWOAVDORUJLA-UHFFFAOYSA-N Rebamipida Chemical compound C=1C(=O)NC2=CC=CC=C2C=1CC(C(=O)O)NC(=O)C1=CC=C(Cl)C=C1 ALLWOAVDORUJLA-UHFFFAOYSA-N 0.000 claims description 2
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 239000002585 base Substances 0.000 claims description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 2
- 229940046731 calcineurin inhibitors Drugs 0.000 claims description 2
- 159000000007 calcium salts Chemical class 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 229960001265 ciclosporin Drugs 0.000 claims description 2
- 239000008139 complexing agent Substances 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 229930182912 cyclosporin Natural products 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 229950003529 diquafosol Drugs 0.000 claims description 2
- 235000019441 ethanol Nutrition 0.000 claims description 2
- 229940012356 eye drops Drugs 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 239000003979 granulating agent Substances 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- 229910003002 lithium salt Inorganic materials 0.000 claims description 2
- 159000000002 lithium salts Chemical class 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 159000000003 magnesium salts Chemical class 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 2
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 229960002969 oleic acid Drugs 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 235000019271 petrolatum Nutrition 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 2
- 229950004535 rebamipide Drugs 0.000 claims description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 2
- 239000001488 sodium phosphate Substances 0.000 claims description 2
- 159000000000 sodium salts Chemical group 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 229940083466 soybean lecithin Drugs 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 150000003462 sulfoxides Chemical group 0.000 claims description 2
- 150000003505 terpenes Chemical class 0.000 claims description 2
- 235000007586 terpenes Nutrition 0.000 claims description 2
- 229960004418 trolamine Drugs 0.000 claims description 2
- 239000003871 white petrolatum Substances 0.000 claims description 2
- 150000003751 zinc Chemical class 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 150000007513 acids Chemical class 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 27
- 239000000203 mixture Substances 0.000 description 27
- 238000000034 method Methods 0.000 description 20
- 206010061218 Inflammation Diseases 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 6
- 206010023332 keratitis Diseases 0.000 description 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 0 *C(c1c(CC2(*)*)c(*)c(C(NC(*)(*)*)=O)c(*)c1)N2I* Chemical compound *C(c1c(CC2(*)*)c(*)c(C(NC(*)(*)*)=O)c(*)c1)N2I* 0.000 description 2
- 208000023328 Basedow disease Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 201000010666 keratoconjunctivitis Diseases 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 206010060742 Endocrine ophthalmopathy Diseases 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 208000031709 Skin Manifestations Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- RYPKRALMXUUNKS-UHFFFAOYSA-N hex-2-ene Chemical group CCCC=CC RYPKRALMXUUNKS-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000001875 irritant dermatitis Diseases 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 206010030983 oral lichen planus Diseases 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 125000000858 thiocyanato group Chemical group *SC#N 0.000 description 1
- 210000001745 uvea Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4524008P | 2008-04-15 | 2008-04-15 | |
| US61/045,240 | 2008-04-15 | ||
| PCT/US2009/002389 WO2009128934A1 (en) | 2008-04-15 | 2009-04-15 | Topical lfa-1 antagonists for use in localized treatment of immune related disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014080832A Division JP2014132032A (ja) | 2008-04-15 | 2014-04-10 | 免疫関連障害に対する局部治療に使用するための局所ｌｆａ−１アンタゴニスト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011521896A JP2011521896A (ja) | 2011-07-28 |
| JP2011521896A5 true JP2011521896A5 (cg-RX-API-DMAC7.html) | 2012-06-07 |
Family
ID=41164200
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011505028A Withdrawn JP2011521896A (ja) | 2008-04-15 | 2009-04-15 | 免疫関連障害に対する局部治療に使用するための局所ｌｆａ−１アンタゴニスト |
| JP2014080832A Pending JP2014132032A (ja) | 2008-04-15 | 2014-04-10 | 免疫関連障害に対する局部治療に使用するための局所ｌｆａ−１アンタゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014080832A Pending JP2014132032A (ja) | 2008-04-15 | 2014-04-10 | 免疫関連障害に対する局部治療に使用するための局所ｌｆａ−１アンタゴニスト |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20090258070A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2265125B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2011521896A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102056485A (cg-RX-API-DMAC7.html) |
| ES (1) | ES2763703T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009128934A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2383525T3 (es) | 2003-11-05 | 2012-06-21 | Sarcode Bioscience Inc. | Moduladores de la adhesión celular |
| JP5794721B2 (ja) * | 2005-05-17 | 2015-10-14 | サーコード バイオサイエンス インコーポレイテッド | 眼障害の治療のための組成物および方法 |
| EP1915620B1 (en) | 2005-08-02 | 2010-06-02 | Xbiotech Inc | DIAGNOSIS, TREATMENT, AND PREVENTION OF VASCULAR DISORDERS USING IL-1alpha AUTOANTIBODIES |
| ES2630406T3 (es) | 2007-10-19 | 2017-08-21 | Sarcode Bioscience Inc. | Composición y procedimientos para el tratamiento de la retinopatía diabética |
| US20090258069A1 (en) * | 2008-04-15 | 2009-10-15 | John Burnier | Delivery of LFA-1 antagonists to the gastrointestinal system |
| US20090257957A1 (en) * | 2008-04-15 | 2009-10-15 | John Burnier | Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders |
| PL2285409T3 (pl) | 2008-05-30 | 2016-10-31 | Przeciwciała il-1 alfa | |
| JP5976319B2 (ja) | 2008-09-12 | 2016-08-23 | エックスバイオテク, インコーポレイテッドXbiotech, Inc. | 病原性単球の標的化 |
| US8962026B2 (en) * | 2008-09-26 | 2015-02-24 | The Regents Of The University Of Michigan | Nanoemulsion therapeutic compositions and methods of using the same |
| EP2395839B1 (en) * | 2009-02-13 | 2014-05-07 | Topica Pharmaceuticals, Inc | Anti-fungal formulation |
| JP2013516459A (ja) * | 2010-01-20 | 2013-05-13 | カディラ・ヘルスケア・リミテッド | ピタバスタチン及び医薬として許容可能なそれらの塩の製造方法 |
| KR20180086297A (ko) | 2010-06-18 | 2018-07-30 | 엑스바이오테크, 인크. | 관절염 치료 |
| KR101910760B1 (ko) | 2010-08-23 | 2018-10-22 | 엑스바이오테크, 인크. | 종양성 질병들에 대한 치료 |
| US9724409B2 (en) | 2011-04-01 | 2017-08-08 | Xbiotech, Inc. | Treatment of inflammatory skin disease |
| CA2849710C (en) | 2011-09-23 | 2020-04-28 | Xbiotech Inc. | Cachexia treatment |
| WO2013108644A1 (ja) * | 2012-01-20 | 2013-07-25 | 京都府公立大学法人 | レバミピドのアレルギー性結膜炎治療剤 |
| US9545441B2 (en) | 2012-09-18 | 2017-01-17 | Xbiotech, Inc. | Treatment of diabetes |
| EP2934510B1 (en) | 2012-12-19 | 2020-10-28 | Novartis AG | Lfa-1 inhibitor formulations |
| US9688943B2 (en) | 2015-05-29 | 2017-06-27 | beauty Avenues LLC | Candle containing non-ionic emulsifer |
| US20200009130A1 (en) * | 2016-12-16 | 2020-01-09 | Sarcode Bioscience Inc. | Ocular distribution and pharmacokinetics of lifitegrast formulations |
| EP3582813A4 (en) | 2017-02-16 | 2020-12-30 | XBiotech, Inc | TREATMENT OF SUPPURATIVE HIDRADENITIS |
| CN106920239B (zh) * | 2017-03-08 | 2019-10-18 | 福建师范大学 | 一种基于改进sift算法的图像关键点检测方法 |
| TW201920956A (zh) * | 2017-09-29 | 2019-06-01 | 日商參天製藥股份有限公司 | 淚液中之muc5ac量之測定方法 |
| CN111787918A (zh) * | 2017-11-29 | 2020-10-16 | 洛克菲勒大学 | 用于皮肤病学病况增强治疗的局部和全身性治疗的组合 |
| KR20220003555A (ko) * | 2019-04-18 | 2022-01-10 | 아주라 오프탈믹스 엘티디 | 안구 장애의 치료를 위한 화합물 및 방법 |
| WO2021010843A1 (en) | 2019-07-16 | 2021-01-21 | Donaghys Limited | Transdermal solvent system and methods of use |
| EP3797771B1 (en) * | 2019-09-03 | 2022-02-23 | Square Power Ltd | Rebamipide for use in prophylaxis and treatment of celiac disease |
| CN112494488B (zh) * | 2020-06-17 | 2022-01-18 | 中国药科大学 | 瑞巴派特的防脱发和生发用途 |
| US12393057B2 (en) * | 2020-12-15 | 2025-08-19 | Coopervision International Limited | Oleic acid-releasing contact lens |
| CA3204617A1 (en) * | 2020-12-29 | 2022-07-07 | Next Science IP Holdings Pty Ltd | Cancer treatment composition and method |
| CA3216947A1 (en) * | 2021-06-14 | 2022-12-22 | Protransit Nanotherapy Llc | Cyclosporine compositions and methods of use thereof |
| CN115707698A (zh) * | 2021-08-18 | 2023-02-21 | 辽宁何氏医学院 | 5,7-二氯-1,2,3,4-四氢异喹啉-6-甲酰胺类化合物及其制备方法和应用 |
| EP4589369A1 (en) * | 2022-09-15 | 2025-07-23 | NOF Corporation | Solution for contact lenses |
| US12161612B2 (en) | 2023-04-14 | 2024-12-10 | Neuroderm, Ltd. | Methods and compositions for reducing symptoms of Parkinson's disease |
| WO2025223511A1 (zh) * | 2024-04-25 | 2025-10-30 | 上海翊石医药科技有限公司 | 一类苯甲酰基甘氨酸衍生物及其制备方法和应用 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4316893A (en) | 1975-06-19 | 1982-02-23 | Nelson Research & Development Co. | Vehicle composition containing 1-substituted azacycloalkan-2-ones |
| US4405616A (en) | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
| US4557934A (en) | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
| US4524008A (en) | 1983-12-16 | 1985-06-18 | E. I. Du Pont De Nemours And Company | Controlled initiation chromium dioxide synthesis |
| US4568343A (en) | 1984-10-09 | 1986-02-04 | Alza Corporation | Skin permeation enhancer compositions |
| US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4783450A (en) | 1987-04-13 | 1988-11-08 | Warner-Lambert Company | Use of commercial lecithin as skin penetration enhancer |
| US5001139A (en) * | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) * | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| DE3802996A1 (de) | 1988-02-02 | 1989-08-10 | Cassella Ag | Verwendung von 2-oxo-pyrrolidin-1-acetamid zur bestimmung der glomerulaeren filtrationsrate beim menschen |
| US5424399A (en) * | 1988-06-28 | 1995-06-13 | The Children's Medical Center Corporation | Human CR3α/β heterodimers |
| US5149780A (en) * | 1988-10-03 | 1992-09-22 | The Scripps Research Institute | Peptides and antibodies that inhibit integrin-ligand binding |
| AU8631991A (en) * | 1990-08-27 | 1992-03-17 | Cetus Corporation | Cd18 peptide medicaments for the treatment of disease |
| US5288854A (en) * | 1990-11-28 | 1994-02-22 | Center For Blood Research, Inc. | Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1 |
| WO1993006865A1 (en) * | 1991-10-04 | 1993-04-15 | The United States of America, represented by The Secretary, Department of Health & Human Services | Treatment of ocular inflammation by blockage of cell adhesion molecules |
| US6764681B2 (en) * | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| US6162432A (en) * | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| WO1993017047A1 (en) * | 1992-02-28 | 1993-09-02 | Board Of Regents, The University Of Texas System | Compositions and methods for the treatment of thermal injury |
| US5298492A (en) * | 1992-08-04 | 1994-03-29 | Schering Corporation | Diamino acid derivatives as antihypertensives |
| AU687755B2 (en) * | 1992-08-21 | 1998-03-05 | Genentech Inc. | Method for treating an LFA-1-mediated disorder |
| US5397791A (en) * | 1993-08-09 | 1995-03-14 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| DE59409322D1 (de) * | 1993-12-03 | 2000-06-08 | Hoffmann La Roche | Essigsäurederivate als Arzneimittel |
| US5470953A (en) * | 1993-12-23 | 1995-11-28 | Icos Corporation | Human β2 integrin α subunit |
| US6228383B1 (en) | 1994-03-03 | 2001-05-08 | Gs Development Ab | Use of fatty acid esters as bioadhesive substances |
| CA2188287A1 (en) | 1994-04-19 | 1995-10-26 | Stephen Benedict | Icam-1/lfa-1 short-chain peptides and method of using same |
| US5585359A (en) * | 1994-09-29 | 1996-12-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| ES2123889T3 (es) * | 1994-11-02 | 1999-01-16 | Merck Patent Gmbh | Antagonistas de receptores de adhesion. |
| US5747035A (en) | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
| ATE342295T1 (de) | 1995-07-28 | 2006-11-15 | Genzyme Corp | Biologische abbaubare multiblokhydrogene und ihre verwendung wie trägerstoffe fur kontrollierte freisetzung pharmakologisch activen werstoffe und gewebekontaktmaterialen |
| CA2272565A1 (en) * | 1996-11-27 | 1998-06-04 | Du Pont Pharmaceuticals Company | Integrin receptor antagonists |
| AR013445A1 (es) | 1997-08-28 | 2000-12-27 | Novartis Ag | Antagonistas de lfa-1 |
| US6541606B2 (en) * | 1997-12-31 | 2003-04-01 | Altus Biologics Inc. | Stabilized protein crystals formulations containing them and methods of making them |
| EA007852B1 (ru) | 1998-03-27 | 2007-02-27 | Джинентех, Инк. | Соединения для лечения расстройств, опосредованных рецепторами адгезии cd11/cd18 |
| US6331640B1 (en) * | 1998-10-13 | 2001-12-18 | Hoffmann-La Roche Inc. | Diaminopropionic acid derivatives |
| US6670321B1 (en) * | 1998-12-30 | 2003-12-30 | The Children's Medical Center Corporation | Prevention and treatment for retinal ischemia and edema |
| ATE330631T1 (de) * | 1999-01-05 | 2006-07-15 | Univ Southern Australia | Antikörperfragmente zur lokalen behandlung von augenerkrankungen |
| EP1028114A1 (en) * | 1999-02-13 | 2000-08-16 | Aventis Pharma Deutschland GmbH | Novel guanidine derivatives as inhibitors of cell adhesion |
| US6605597B1 (en) * | 1999-12-03 | 2003-08-12 | Cv Therapeutics, Inc. | Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives |
| US6294522B1 (en) * | 1999-12-03 | 2001-09-25 | Cv Therapeutics, Inc. | N6 heterocyclic 8-modified adenosine derivatives |
| EP1237575B1 (en) * | 1999-12-14 | 2008-08-06 | Genentech, Inc. | Tnf-alpha antagonist and lfa-1 antagonist for treating rheumatoid arthritis |
| US6630447B2 (en) | 2000-01-14 | 2003-10-07 | University Of New Mexico | Peptide inhibitors of LFA-1/ICAM-1 interaction |
| US6515124B2 (en) | 2000-02-09 | 2003-02-04 | Hoffman-La Roche Inc. | Dehydroamino acids |
| WO2001085677A1 (fr) * | 2000-05-05 | 2001-11-15 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Derives d'aminoacides et leur application a titre de medicaments |
| CA2414461A1 (en) * | 2000-06-29 | 2002-01-10 | Abbott Laboratories | Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
| PE20020420A1 (es) * | 2000-10-02 | 2002-06-27 | Novartis Ag | Derivados de diazacicloalcanodiona como antagonistas del antigeno asociado a la funcion del linfocito-1 (lfa-1) |
| US6653478B2 (en) * | 2000-10-27 | 2003-11-25 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators |
| GB0028367D0 (en) * | 2000-11-21 | 2001-01-03 | Celltech Chiroscience Ltd | Chemical compounds |
| CN1592746A (zh) | 2000-11-28 | 2005-03-09 | 杰南技术公司 | Lfa－1拮抗剂化合物 |
| ATE348829T1 (de) * | 2001-02-06 | 2007-01-15 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen |
| AU2002250236A1 (en) * | 2001-03-02 | 2002-09-19 | Medimmune, Inc. | Cd2 antagonists for treatment of autoimmune or inflammatory disease |
| US6391290B1 (en) * | 2001-03-21 | 2002-05-21 | Schering-Plough Healthcare Products, Inc. | Skin care compositions |
| US6872382B1 (en) * | 2001-05-21 | 2005-03-29 | Alcon, Inc. | Use of selective PDE IV inhibitors to treat dry eye disorders |
| IL159203A0 (en) * | 2001-06-06 | 2004-06-01 | Aventis Pharma Ltd | Substituted tetrahydroisoquinolines for use in the treatment of inflammatory diseases |
| CA2454618C (en) * | 2001-07-24 | 2012-04-03 | Biogen Idec Ma, Inc. | Methods for treating or preventing sclerotic disorders using cd2-binding agents |
| RU26988U1 (ru) | 2002-05-06 | 2003-01-10 | Закрытое акционерное общество "ДУКС-ЛИЗИНГ" | Кондуктор для сверления отверстий |
| WO2003103587A2 (en) * | 2002-06-06 | 2003-12-18 | Dana-Farber Cancer Institute | Compounds or agents that inhibit and induce the formation of focal microvessel dilatations |
| US7785578B2 (en) * | 2002-10-11 | 2010-08-31 | Aciont, Inc. | Non-invasive ocular drug delivery |
| CN1902195B (zh) * | 2003-11-05 | 2016-03-23 | 萨可德生物科学公司 | 细胞粘着调节剂 |
| ES2383525T3 (es) * | 2003-11-05 | 2012-06-21 | Sarcode Bioscience Inc. | Moduladores de la adhesión celular |
| WO2005065668A2 (en) * | 2003-12-29 | 2005-07-21 | Qlt Usa, Inc. | Topical compositions comprising halo-deoxyadenosines for treatment of skin disorders |
| EP1756163A2 (en) * | 2004-06-09 | 2007-02-28 | Genentech, Inc. | Method of treating granuloma annulare or sarcoid |
| JP2008507552A (ja) * | 2004-07-22 | 2008-03-13 | ワイス | 神経系障害および状態の治療方法 |
| JP5794721B2 (ja) * | 2005-05-17 | 2015-10-14 | サーコード バイオサイエンス インコーポレイテッド | 眼障害の治療のための組成物および方法 |
| ES2630406T3 (es) * | 2007-10-19 | 2017-08-21 | Sarcode Bioscience Inc. | Composición y procedimientos para el tratamiento de la retinopatía diabética |
| US8080562B2 (en) * | 2008-04-15 | 2011-12-20 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
| US20090257957A1 (en) * | 2008-04-15 | 2009-10-15 | John Burnier | Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders |
| US20090258069A1 (en) * | 2008-04-15 | 2009-10-15 | John Burnier | Delivery of LFA-1 antagonists to the gastrointestinal system |
| WO2011050175A1 (en) * | 2009-10-21 | 2011-04-28 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
| SI3715345T1 (sl) * | 2012-07-25 | 2024-07-31 | Bausch + Lomb Ireland Limited | Priprava zaviralca lfa-1 |
-
2009
- 2009-04-15 ES ES09733509T patent/ES2763703T3/es active Active
- 2009-04-15 CN CN2009801216301A patent/CN102056485A/zh active Pending
- 2009-04-15 JP JP2011505028A patent/JP2011521896A/ja not_active Withdrawn
- 2009-04-15 US US12/386,359 patent/US20090258070A1/en not_active Abandoned
- 2009-04-15 EP EP09733509.5A patent/EP2265125B1/en active Active
- 2009-04-15 EP EP19191575.0A patent/EP3632444A3/en not_active Withdrawn
- 2009-04-15 WO PCT/US2009/002389 patent/WO2009128934A1/en not_active Ceased
-
2013
- 2013-08-07 US US13/961,117 patent/US20140051722A1/en not_active Abandoned
-
2014
- 2014-04-10 JP JP2014080832A patent/JP2014132032A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011521896A5 (cg-RX-API-DMAC7.html) | ||
| JP2011518155A5 (cg-RX-API-DMAC7.html) | ||
| JP2011516607A5 (cg-RX-API-DMAC7.html) | ||
| SK147493A3 (en) | Antialergic substances for the use in ophthalmologic and otorhynologic | |
| US7084157B2 (en) | Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation | |
| KR20090114398A (ko) | (ｅ)-2,6-다이알콕시스티릴 4-치환된 벤질설폰의 비경구 투여용 제형 | |
| US20060014786A1 (en) | Opthalmic pharmaceutical compositions and methods for treating ocular inflammation | |
| US12290497B2 (en) | Agent containing 4-phenylbutyrate, for preventing or treating presbyopia | |
| JP3131693B2 (ja) | 眼疾患を処置するための５―メチル―イソオキサゾール―４―カルボン酸アニリド類または２―ヒドロキシエチリデン―シアノ酢酸アニリド類含有医薬組成物 | |
| US11241426B2 (en) | Aqueous composition for ophthalmic or nasal administration | |
| US11331311B2 (en) | Prophylactic and/or therapeutic agent containing pyridylaminoacetic acid compound | |
| EP1889620A1 (en) | Eye drop containing roflumilast | |
| JP2003128549A (ja) | 粘膜適用組成物 | |
| JPH06316519A (ja) | 薬剤で誘導される瞳孔拡大を抑制し又は拡大された瞳孔を 縮小するための、一定のスルファモイル置換フェネチルア ミン誘導体の使用、及びそれに用いる局部的投与組成物 | |
| PL208284B1 (pl) | Pochodne benzo[g]chinoliny, kompozycje je zawierające oraz zastosowanie takich pochodnych | |
| JP5214966B2 (ja) | ２−アミノ−１，３−プロパンジオール化合物およびその類似体の製剤 | |
| EP4099986B1 (en) | Xanthan-based ophthalmic topical formulations with a reduced dosage regimen | |
| JP2016210780A (ja) | アゾール系抗真菌薬の眼瞼皮膚への投与 | |
| JP7682103B2 (ja) | シロリムスまたはその塩を含有する水性懸濁組成物 | |
| JP2020514347A (ja) | チオトロピウムを有効成分として含有する近視予防、近視治療および／または近視進行抑制剤 | |
| CN101432000B (zh) | 用于变应性眼病或变应性鼻病的包含三环性三唑并苯并氮杂*衍生物的预防剂或治疗剂 | |
| JP4779382B2 (ja) | 点眼剤用組成物 | |
| KR20160072829A (ko) | 테노포비어, 항균제 및 선택적으로 시클로피록스를 포함하는 국소 약학 조성물 | |
| JP2003201250A (ja) | 掻痒治療剤 | |
| US20080015255A1 (en) | Pharmaceutical Compositions Based on Fluorinated Sulphamides and Sulphinimides |